A 68-year-old man noted redness in his left eye (operating system, OS) for 6 months. Visual acuity was 20/25 right eye and 20/20 OS. Examination revealed bilateral corneal furrow degeneration and coincidental foreign body "rust ring."\[[@ref1][@ref2]\] \[[Fig. 1](#F1){ref-type="fig"}\] A sessile papillary squamous cell neoplasm was found OS. This measured 10 mm in diameter and overhung the cornea \[Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\].\[[@ref3]\] Anterior segment optical coherence tomography (AS-OCT; Visante OCT 3.0; Carl Zeiss Meditec, Dublin, CA) confirmed 1-2 mm of peripheral corneal thinning.\[[@ref4]\] \[[Fig. 4](#F4){ref-type="fig"}\] Fluorescein angiography established intrinsic tumor vascularity \[[Fig. 5](#F5){ref-type="fig"}\]. Tumor was surgically managed with "no touch" excision, dry keratectomy without alcohol application, cryotherapy, and primary double-layer closure.\[[@ref3]\] Histopathology disclosed squamous cell carcinoma *in situ* (CIS) of conjunctival epithelium. Tumor cells were immunoreactive for squamous cell carcinoma marker p63 \[Figs. [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}\].

![Bilateral corneal furrow degeneration with additional "rust ring" (arrow) right eye and vascular mass (arrow-head) left eye](IJO-62-809-g001){#F1}

![Sessile, vascular conjunctival epithelial tumor left eye](IJO-62-809-g002){#F2}

![Corneal furrow degeneration with peripheral corneal thinning (arrow-head) and conjunctival tumor overlying cornea (arrow)](IJO-62-809-g003){#F3}

![Anterior segment optical coherence tomography confirms peripheral corneal thinning consistent with corneal furrow degeneration (arrow)](IJO-62-809-g004){#F4}

![Fluorescein angiography highlights vascular pattern of conjunctival tumor](IJO-62-809-g005){#F5}

![Histopathology discloses sessile papillomatous proliferatoin of atypical squamous cells consistent with squamous cell carcinoma *in situ* (CIS). Intralesional vessels and characteristic abrupt margin between normal epithelium and the thick plaque of atypical squamous cells are seen in higher magnification image below. (H and E, top × 25, bottom ×100)](IJO-62-809-g006){#F6}

![Atypical squamous cells comprising conjunctival intraepithelial neoplasia (CIN) show positive nuclear staining (brown color) for p63, an immunohistochemical marker for squamous cell carcinoma. (Immunohistochemistry P63, ×250)](IJO-62-809-g007){#F7}

Discussion {#sec1-1}
==========

Corneal furrow degeneration is painless, bilateral thinning of peripheral cornea between corneal arcus and limbus, predominantly affecting elderly. Commonly, there is no inflammation, vascularization, or induced corneal astigmatism. Subjects are usually asymptomatic. Depending on severity, management involves observation, lubrication, or punctal occlusion.\[[@ref1][@ref2]\]

Conjunctival squamous cell carcinoma in situ (CIS) of conjunctival epithelium is a malignant neoplasm that usually arises from limbal stem cells. Part of the spectrum of conjunctival intraepithelial neoplasia (CIN), it may invade through epithelial basement membrane into the conjunctival or corneal stroma or rarely the interior of eye or orbit. Corneal furrow degeneration is not associated with higher incidence of CIN or related malignancies, despite the similar location. Management of CIN involves alcohol-assisted de-epithelialization of CIN, complete tumor removal, cryotherapy of margins, and tissue closure. In this case, alcohol was not used for possible risk of corneal perforation in degenerated corneal guttter.\[[@ref3][@ref5]\] Similarly, topical steroids or 5-fluorouracil were avoided. Post-operative healing was unremarkable. In such cases, alteration of surgical technique should be considered.
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